Have to say that I disagree with their probability for success of LANI and the potential market size, but anyhow good to see someone out there is watching.
http://www.biota.com.au/uploaded/154/1021394_10abnamromorgansbta10808-.pdf
Target price $1.29 (72% from these levels and using what looks like conservative valuation measures).
Trouble is, there is little news for a while... perhaps HRV testing but I fear that the market will write off Biota for a while due to bad sentiment from the GSK settlement. A deal for LANI should reverse that but now the Phase II worked well in a large patient sample I personally wouldn't mind if Biota waited till phase III completed before partnering the compound. Then again, GSK are probably sniffing some sort of partnership deal.
Does anyone have a reference where Biota management suggested even GSK could be a potential partner for LANI. I remember seeing or hearing it somewhere but for the life of me I just can't remember. Perhaps a news interview?
upgrade from abn amro
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)